CD8A and myeloid sarcoma: Overall, our findings implicate CD20-expressing T cells, especially CD8+ T cells, in early MS relapse biology and imply that the impact of aCD20 initiation could depend on the timing with which treatment is instituted relative to already developing relapse biology.